Literature DB >> 15522884

Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318.

Tong Shi1, Bill Giannakopoulos, G Michael Iverson, Keith A Cockerill, Matthew D Linnik, Steven A Krilis.   

Abstract

The fifth domain (DV) of beta2-glycoprotein I (beta2GPI) is important for binding a number of ligands including phospholipids and factor XI (FXI). Beta2GPI is proteolytically cleaved in DV by plasmin but not by thrombin, VIIa, tissue plasminogen activator, or uPA. Following proteolytic cleavage of DV by plasmin, beta2GPI retains binding to FXI but not to phospholipids. Native beta2GPI, but not cleaved beta2GPI, inhibits activation of FXI by thrombin and factor XIIa, attenuating a positive feedback mechanism for additional thrombin generation. In this report, we have defined the FXI/FXIa binding site on beta2GPI using site-directed mutagenesis. We show that the positively charged residues Lys284, Lys286, and Lys287 in DV are essential for the interaction of beta2GPI with FXI/FXIa. We also demonstrate that FXIa proteolytically cleaves beta2GPI at Lys317-Thr318 in DV. Thus, FXIa cleavage of beta2GPI in vivo during thrombus formation may accelerate FXI activation by decreasing the inhibitory effect of beta2GPI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522884     DOI: 10.1074/jbc.M410291200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2).

Authors:  Tara C White-Adams; Michelle A Berny; Erik I Tucker; Jacqueline M Gertz; David Gailani; Rolf T Urbanus; Philip G de Groot; András Gruber; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

2.  Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H.

Authors:  Cristina Puy; Jiaqing Pang; Stéphanie E Reitsma; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Florea Lupu; Owen J T McCarty
Journal:  J Immunol       Date:  2021-04-15       Impact factor: 5.422

3.  Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

Authors:  Taro Sakai; Krishnakumar Balasubramanian; Sourindra Maiti; Jyotsna B Halder; Alan J Schroit
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

4.  Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome.

Authors:  Fatima El-Assaad; Steven A Krilis; Bill Giannakopoulos
Journal:  Thromb J       Date:  2016-10-04

5.  A proteolytic modification of AIM promotes its renal excretion.

Authors:  Tomoko Yamazaki; Ryoichi Sugisawa; Emiri Hiramoto; Ryosuke Takai; Ayaka Matsumoto; Yoshie Senda; Katsuhiko Nakashima; Peter S Nelson; Jared M Lucas; Andrew Morgan; Zhenghua Li; Ken-Ichi Yamamura; Satoko Arai; Toru Miyazaki
Journal:  Sci Rep       Date:  2016-12-08       Impact factor: 4.379

Review 6.  Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS".

Authors:  Roberta Misasi; Agostina Longo; Serena Recalchi; Daniela Caissutti; Gloria Riitano; Valeria Manganelli; Tina Garofalo; Maurizio Sorice; Antonella Capozzi
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

7.  Prochemerin cleavage by factor XIa links coagulation and inflammation.

Authors:  Xiaomei Ge; Yasuto Yamaguchi; Lei Zhao; Loredana Bury; Paolo Gresele; Caroline Berube; Lawrence L Leung; John Morser
Journal:  Blood       Date:  2017-11-20       Impact factor: 25.476

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.